ICIs have offered new hope for cancer patients, especially for those with immune-active tumors classified as “hot tumors”, cancers whose microenvironment is already inflamed, with dense CD8+ T-cell infiltration, high interferon-γ signaling, and abundant PD-L1 expression. Here, CD8A is linked to cancer.